ADIAL PHARMACEUTICALS, INC. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 88/100
What the filing says
Adial Pharmaceuticals (market cap ~$6.5M) filed an 8-K on August 21, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has received notice of non-compliance with exchange listing standards, though the specific rule violation, timeline for cure, and exchange are not detailed in this filing header. The filing documents show standard SEC submission files but do not provide the substantive disclosure required to assess the severity or remediation pathway.
Why this rating
Delisting notice is business-threatening for micro-cap; potential loss of public market access, liquidity collapse, and regulatory burden are existential risks.
Extracted items
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.